Autoimmune in Menopause and Pregnancy Transitions

Women represent 4 out of 5 autoimmune disease patients, more than 400 million women globally.1,2 Autoimmune disease costs each affected woman 4 to 9 healthy, productive years over a lifetime, the equivalent of losing 1 or more days every week to pain, fatigue, and joint swelling.3 Despite this disproportionate impact, no existing therapy addresses a woman’s unique risk or its biological causes. What accounts for the disproportionate risk women experience, and what can be done to reduce it?

Why women?

A woman’s risk for autoimmune disease is not fixed; risk rises and falls with her hormone transitions, surging at puberty, after childbirth, and around menopause. In the 3 months after the birth of her first child, a woman’s risk of developing rheumatoid arthritis (RA) rises about 5-fold.4 If she reaches menopause before 45, her risk of seronegative RA more than doubles.5 Multiple sclerosis (MS) quiets in the third trimester of pregnancy, then relapses rise 6-fold postpartum.6 Across the menopausal transition, markers of nerve-cell injury rise and neurologic function declines,7 and disability progression is nearly twice as common after menopause.8 Lupus tracks hormone transitions differently. Flares are nearly twice as common in pregnancy,9 activity rises in the late postpartum months,10 and again in the final year of perimenopause.11

The timing is not a coincidence. The timing is the signal. Estrogen dynamically regulates self-tolerance, the immune system’s ability to distinguish the body’s own tissues from foreign threats, and as estrogen rises and falls across a woman’s life, self-tolerance shifts with it.12–14 Yet autoimmune disease models fail to incorporate immune–endocrine state, or to distinguish true hormonal state from chronological aging, and no therapy is guided by a woman’s immune–endocrine transitions.

Estrogen is a rheostat for the immune system

Immune cells carry estrogen receptors, and through them estrogen tunes how strongly the immune system reacts while preserving self-tolerance.15,16 Estrogen acts on 2 dials. Central tolerance, operating in the thymus, screens out self-reactive T cells before they enter the bloodstream. Rising estrogen lowers the efficiency of this screening by downregulating the thymic protein AIRE.14 Peripheral tolerance, the backup, is enforced by regulatory T cells (Tregs). Estrogen expands Tregs and strengthens their immune-suppressive capacity.13,17,18 Tregs rise in pregnancy, deepening immune tolerance to the developing fetus; after delivery, when MS and RA flares cluster, Tregs decline.19 At menopause, estrogen’s lasting decline impairs Treg function20 and tips the balance toward inflammation.21

One lever, different effects. The direction estrogen tips the immune system depends on its level, the local tissue context, and timing. In RA and MS, disease tends to quiet under the high estrogen of pregnancy and flare when estrogen withdraws after delivery, a pattern that points to peripheral tolerance. Lupus runs the opposite way, worsening when estrogen is high. In lupus the dominant players are self-reactive B cells, the immune cells that generate autoantibodies directed at the body’s own DNA, proteins, and cells, which drive inflammation. Estrogen promotes self-reactive B cell survival and autoantibody output, so the same high-estrogen state that calms RA and MS inflames lupus. One hormone, acting through different immune routes, protects in some diseases and provokes in others. These 3 diseases, spanning opposite ends of that spectrum, are the program’s index cases.

A high burden at pivotal chapters

RA, MS, and lupus affect nearly 20 million women globally, who together forfeit more than 6 million healthy life-years each year. All 3 diseases are growing, with RA alone projected to affect more than 30 million people by 2050.22 After onset, RA costs a woman about 1.8 days a week, MS 2.5, and lupus 3.3. Those lost days fall disproportionately at 2 chapters.

The first chapter is the year after childbirth. More than 500,000 women a year face their sharpest rise in disease activity postpartum: more than a quarter of women with MS relapse within 3 months,6 and close to 2 in 5 women with RA flare.23 For others the postpartum period brings disease onset, with RA risk roughly 5 times higher than at other times4, with an estimated 30,000 new RA cases a year traced to this window alone.

The second chapter is the menopausal transition. A woman’s risk of RA rises about a third after menopause and nearly triples when menopause is early.24 The largest analysis found confirmed MS disability progression in 56% of women after menopause versus 32% before.8 Estrogen does not simply fade at menopause, it rises and falls erratically, and the instability tracks with disease: in the year before the final period, cutaneous lupus flares triple.11

What needs to change?

Sex hormones act directly on the immune cells driving autoimmune disease, yet immune–endocrine interactions at hormone transitions go unmeasured. Rheumatology and neurology record immune markers and file reproductive stage under “background”; endocrinology measures hormones but ignores immune signatures. The 2 are rarely measured together. Women are grouped by age rather than hormone status, however age is a poor substitute for tracking a hormone transition. When hormone therapies have been tested in autoimmune disease, they were given without adequate attention to timing or dose.26

What if greater precision lets treatment be designed and delivered in a window before damage is done? A woman’s hormone levels are often already captured in routine care, or can be measured directly, and her immune state quantified from a small blood sample. The 2 are linked. Tracking them together through the transitions when risk shifts would let us model the precursors of disease and predict its onset. For women already living with these diseases, it would mean anticipating a flare and treating before it strikes rather than chasing it afterward.

Goal of the program

AMPt aims to build immune–endocrine models capable of predicting a woman’s risk of autoimmune onset or flare with enough accuracy to design and deliver effective treatment. The goal is to return the equivalent of 1 healthy day a week to millions of women living with RA, MS, or lupus — as many as 52 healthy days a year, and up to 5 years across a lifetime. Achieving the goal requires predicting flares at least 4 weeks ahead and new disease at least 12 weeks ahead, catching seronegative RA inside its ~12-week treatment window, and together cutting the rate of flares and new disease by at least a third.

Thrust 1 — Measure and model

Build a dynamic immune–endocrine model that forecasts flare and new-onset disease with ≥80% sensitivity and specificity at the postpartum and menopausal transitions, and resolves, per disease, whether higher or lower estrogen is tolerogenic or provocative. Trained on densely sampled longitudinal cohorts spanning menstruation, pregnancy, and menopause, the model returns a woman’s risk as a continuous score, her position on the immune tolerogenic–provocative axis, and the pathway driving it. The model forecasts a flare at least 4 weeks ahead and postpartum onset at least 12 weeks ahead, better than a baseline of prior disease activity plus age, and replicated across at least 2 independent cohorts.

Thrust 2 — Predict

Validate a biomarker panel that reads a woman’s immune–endocrine state from a routine blood draw, with enough lead time to act: start a disease-modifying drug, and/or the hormone therapy of Thrust 3, before a flare or onset. The panel must retain ≥80% sensitivity and specificity under clinical-lab conditions, forecasting flare in established RA, MS, or lupus at least 4 weeks ahead and new-onset RA at least 12 weeks ahead. A companion diagnostic targets seronegative RA across the menopause transition, the form that rises after menopause and carries none of the antibodies standard tests rely on,5 classifying it at presentation at ≥80% sensitivity and specificity, so treatment can begin inside the window that prevents irreversible joint damage.

Thrust 3 — Intervene

Assess interventions dosed and timed to hormone transitions: a serum-guided hormone taper that smooths the abrupt postpartum and erratic perimenopausal fall, or a disease-modifying therapy timed to the transition, targeting a reduction of at least a third in postpartum flares and menopausal disease progression versus current care. A pumping sub-study measures how much exogenous hormone passes into milk, with the aim of delivering lactation-safe and hormone-timed protocols ready for later testing.

Success would return an estimated 9.2 million healthy days to women each year through earlier prediction and flare prevention, including ~3.6 million from diagnosing seronegative RA sooner, and roughly 63 million healthy days over the lifetime of each year’s prevented new cases.